$11.12
Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
HUTCHMED to Announce 2026 Half-Year Financial Results
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
Overview
52-week range
$11
$20
5% of range
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Latest IV / EM
197%
EM ±45.0% · $10 · Aug 21
Earnings trends
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | — | — |